In 2020, almost 325,000 people globally were diagnosed with
melanoma — a type of skin cancer and umber of people with melanoma will
increase to 510,000 cases worldwide by 2040.About half of the people
treated for melanoma will have a recurrence.Researchers recently presented phase 2b clinical trial results showing a
combination of an mRNA vaccine and immunotherapy helps reduce the
likelihood of melanoma recurrence in people who had surgery to remove
melanoma from lymph nodes or other organs.
melanoma — a type of skin cancer and umber of people with melanoma will
increase to 510,000 cases worldwide by 2040.About half of the people
treated for melanoma will have a recurrence.Researchers recently presented phase 2b clinical trial results showing a
combination of an mRNA vaccine and immunotherapy helps reduce the
likelihood of melanoma recurrence in people who had surgery to remove
melanoma from lymph nodes or other organs.
The researchers combined the experimental vaccine mRNA-4157/V940 and the
immunotherapy pembrolizumab in patients with melanoma.The American
Association for Cancer Research, showing a combination of an experimental
mRNA vaccine with immunotherapy helps reduce the likelihood of melanoma
recurrence in people who had surgery to remove melanoma from lymph nodes or
other organs and were at high risk for recurrence.
